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Background: Recent research has used cardiovascular risk scores intended to estimate “total cardiovascular disease
(CVD) risk” in individuals to assess the distribution of risk within populations. The research suggested that the
adoption of the total risk approach, in comparison to treatment decisions being based on the level of a single risk
factor, could lead to reductions in expenditure on preventive cardiovascular drug treatment in low- and middle-
income countries. So that the patient benefit associated with savings is highlighted.
Methods: This study used data from national STEPS surveys (STEPwise Approach to Surveillance) conducted
between 2005 and 2010 in Cambodia, Malaysia and Mongolia of men and women aged 40–64 years. The study
compared the differences and implications of various approaches to risk estimation at a population level using the
World Health Organization/International Society of Hypertension (WHO/ISH) risk score charts. To aid interpretation
and adjustment of scores and inform treatment in individuals, the charts are accompanied by practice notes about
risk factors not included in the risk score calculations. Total risk was calculated amongst the populations using the
charts alone and also adjusted according to these notes. Prevalence of traditional single risk factors was also
calculated.
Results: The prevalence of WHO/ISH “high CVD risk” (≥20% chance of developing a cardiovascular event over 10
years) of 6%, 2.3% and 1.3% in Mongolia, Malaysia and Cambodia, respectively, is in line with recent research when
charts alone are used. However, these proportions rise to 33.3%, 20.8% and 10.4%, respectively when individuals
with blood pressure > = 160/100 mm/Hg and/or hypertension medication are attributed to “high risk”. Of those at
“moderate risk” (10- < 20% chance of developing a cardio vascular event over 10 years), 100%, 94.3% and 30.1%,
respectively are affected by at least one risk-increasing factor. Of all individuals, 44.6%, 29.0% and 15.0% are affected
by hypertension as a single risk factor (systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg or medication).
Conclusions: Used on a population level, cardiovascular risk scores may offer useful insights that can assist health
service delivery planning. An approach based on overall risk without adjustment of specific risk factors however,
may underestimate treatment needs.
At the individual level, the total risk approach offers important clinical benefits. However, countries need to develop
appropriate clinical guidelines and operational guidance for detection and management of CVD risk using total
CVD-risk approach at different levels of health system. Operational research is needed to assess implementation
issues.* Correspondence: otgon_phi@hotmail.com
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Cardiovascular disease (CVD), largely heart disease and
stroke, accounts for almost half of all NCD-related
deaths and is now the leading cause of death in low- and
middle-income countries (LMIC). Nearly 58% of CVD
deaths in LMICs are in those aged less than 60 com-
pared with just 20% in high-income countries (HICs)
[1,2].
A reduction of CVD morbidity and premature mortal-
ity has been achieved through a combination of three
strategies: population-level risk factor reduction strat-
egies; individual-based primary prevention strategies
targeted at high-risk groups to prevent the onset of
CVD through risk factor reduction; and secondary pre-
vention and treatment to prevent disease progression in
people with established CVD [3]. Research from several
countries has consistently shown that treatments of
established CVD explain less of the decline than reduc-
tions in risk factors to prevent development of cardio-
vascular disease. Between 42% and 60% of the decline in
CVD deaths has been attributed to changes in risk fac-
tors including reduction in total cholesterol, systolic
blood pressure and smoking prevalence, while 23% to
47% was attributed to treatments including secondary
preventive therapies [4-9].
Individual-based primary prevention strategies can in-
volve two approaches. First is the ‘vertical’ approach that
involves management of each of the single risk factors such
as hypertension or hypercholesterolemia according to pre-
defined thresholds for treatment initiation irrespective of
the presence or absence or levels of concomitant risk fac-
tors. The second approach calls for treatment decisions
based on assessment of an individual’s “total’’ predicted risk
of developing a cardiovascular event - such as myocardial
infarction or stroke over next five or ten years. Total CVD
risk is determined according to charts or equations that
take into account the co-existence in an individual of a
range of risk factors such as age, sex, tobacco use, body
mass index, diabetes, raised blood pressure and a variety of
biochemical indicators. Recent research suggests that com-
pared with the vertical treatment approach, adopting
pharmaceutical treatment strategies based on the total
CVD risk assessment approach offers considerable savings
[10,11]. The 2007 WHO guidelines for primary prevention
of CVD recommend the second approach by targeting lim-
ited healthcare resources most cost-effectively at high-risk
groups to prevent CVD [12].
The total risk scores are based upon multivariate risk
analyses of longitudinal cohorts that ascribe values to
different risk factors [13]. Since the publication of the
first risk scores from the Framingham Heart Study in
1976 [14], many scores have been developed and are in
use from other cohort studies, mainly in developed
countries involving Caucasian populations [15-21]. Thescores vary widely in terms of study characteristics, pre-
dictors and CVD outcomes investigated [22]. Risk scores
based upon studies conducted in HIC may not be suit-
able for use in low-resource settings. Therefore the
World Health Organization and the International Soci-
ety of Hypertension (WHO/ISH) developed sets of re-
gional risk prediction charts based on fewer risk factors
that can be assessed by physicians and non-physician
health workers in primary care setting for CVD preven-
tion in each of the fourteen WHO subregions [12].
Although the CVD risk scores are designed for use by
clinicians for quick and consistent estimation of total
CVD risk in ‘individuals’, these can also be used to esti-
mate and monitor population distribution of CVD risk
from cross-sectional survey of population samples
[10,11]. National health planners may use population-
distribution of total CVD risk to assess total preventive
needs and associated costs as well as to monitor net-
effectiveness of interventions that affect multiple CVD
risk factors by different magnitudes and direction [23].
Few LMIC currently have clinical guidelines either for
screening or treatment of risk factors based on ‘total’
CVD risk scores and few have estimated population-
distribution of CVD risk over time. Using nationally rep-
resentative population data, this study provides first-ever
estimates of population-distribution of CVD risk in three
LMICs (Cambodia, Mongolia, and Malaysia) countries at
different stages of socio-economic, demographic and
epidemiological transition. The study assesses the popu-
lation distribution of total CVD risk estimated using the
WHO/ISH risk charts alone, and the effect that inclu-
sion of different criteria has on those distribution esti-
mates in all three countries. The paper considers the
issues that may be associated with using the total risk
approach both at a population- and at individual-level in
low-income settings.Study context
Malaysia is an upper middle-income country of some 28
million people, a newly industrialized market economy
with GDP of 287.9 billion. Mongolia, one of the least
densely populated countries with a population of less
than 3 million, is a lower-middle-income country with
GDP of 8.761 billion, is a country with a growing econ-
omy centered on agriculture and mining. Cambodia, a
low-income country with GDP 12.83 billion and a coun-
try of more than 13 million people, remains largely agri-
cultural and rural, although it has seen industrial and
economic growth in recent years [24,25]. In each of the
countries the impact of NCDs is significant: NCDs ac-
count for more than 50% of life years lost in Malaysia
and Mongolia and 31% in Cambodia [26]. Life-
expectancy at birth in Malaysia was 74 years as of 2011,
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Cambodia [27].
Methods
The study used data from national STEPS surveys
(STEPwise Approach to Surveillance) conducted be-
tween 2005 and 2010 in Cambodia, Malaysia and
Mongolia (Table 1). STEPS surveys are cross-sectional
surveys that combine interviews and physical examina-
tions and use standardized questionnaires and measure-
ment protocols. The WHO Geneva STEPS team
provides global coordination for STEPS implementation
across the regions. WHO delivers and funds STEPS
methodology manuals and regional training workshops
that cover all aspects of planning, implementation, ana-
lysis and reporting of the surveys. The surveys yield na-
tionally representative data on selected NCD risk
factors, comparable between countries. The survey
methodology has been described in detail elsewhere
[28-31]. In brief, each survey used multi-stage stratified
cluster random sampling to select a nationally represen-
tative cohort of participants 25–64 years old (15–64 years
in Mongolia). Sampled individuals were interviewed in
person to elicit information on selected demographic
and socio-economic characteristics, tobacco and alcohol
use, dietary intake, physical activity, and diagnosis and
treatment history for hypercholesterolemia (only inTable 1 Survey sample sizes, sex and age, response rates and
Cambodia





Sample size aged (25–64) 5,433
Sample size aged (40–64 years) 3244
Sample size aged 40–64 years with
data on DM & HT & included in the





Age in years: mean (SD)
Unweighted 49.7 (0.15)
Weighted 50.7 (0.12)
Measurement of Blood pressure
(measured 3 times in sitting position)
NISSEI Digital Blood Pressure
Monitor (Model DS-500)
Measurement of fasting Blood/plasma
sugar and cholesterol
Whole capillary blood taken from
fingertips; dry chemical reagent
strips & Accutrend GCT instrumen
1 Biochemical measurements were carried out only on one-third of total sampled pMalaysia), diabetes and hypertension. The health exam-
ination element included measurements of height,
weight, blood pressure, resting pulse rate, and collection
of blood samples for biochemical measurements (Chol-
esterol and blood/plasma glucose). All sampled adults
provided written informed consent and the surveys were
approved by National Ethics Committee for Health Re-
search of Ministry of Health in Cambodia and by the
Medical Ethical Committee of the Ministry of Health in
Mongolia and by Medical Research Ethics Committee in
Malaysia.
Table 1 summarizes the sample sizes, response rates
and measurement methods. This study includes only the
sampled population aged 40–64 years, as the WHO/ISH
risk score is designed for population only 40 years and
older.
Calculating total CVD risk using WHO/ISH risk prediction
charts
We calculate the total CVD risk of the sampled individ-
uals using WHO/ISH risk assessment charts for the
Western Pacific B sub-region (WPR B). WHO/ISH have
devised two sets of risk prediction charts—with and
without blood cholesterol [12,32]. The former requires
data on sex (male/female), age (measured in single
years), systolic blood pressure (in mmHg), total serum
cholesterol (in mmol/l), current smoking status (yes/no)measurement methods
Malaysia Mongolia


















5 ml venous blood; plasma glucose: enzymatic
assay kit (GlucoseFlex® reagent cartridge); total
cholesterol: enzymatic colorimetric tests
Same as in
Cambodia
opulation in the age group 25–64 years old in Mongolia.
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for all cases with these data available. For individuals
with missing cholesterol data we used the no-cholesterol
charts. Research has shown that the risk scores were
similar between the two charts in both men and women
for fatal events [33]. For total CVD risk calculation, a
person was categorized as smoker who reported smok-
ing currently or those who reported as currently non-
smokers but reported quitting smoking less than 1 year
before the survey. Diabetes was defined as having
survey-measured fasting blood glucose ≥ 6.1 mmol/l or
110 mg/dl (whole blood) or ≥ 7.0 mmol/l or 126 mg/dl
(blood plasma), or having measured blood sugar below
these thresholds but reported using insulin or oral
hypoglycemic drugs at the time of survey. Systolic blood
pressure was the mean of last two of the three measure-
ments taken in rested participants in sitting position at
the time of survey. Total cholesterol levels were mea-
sured in mmol/l as described in Table 1. The risk cat-
egories for 10-year total risk of a fatal or non fatal CVD
event include <10% classified as “low risk”, 10- < 20%
“moderate risk”, 20- < 30% as high risk and ≥ 30% as
“very high risk” [12,32].
WHO/ISH risk score charts are accompanied by prac-
tice notes for clinicians to aid interpretation and adjust-
ment of individuals’ risk when other risk factors are
present that are not included in the risk score calcula-
tions. These notes are not always used in studies that
have applied the risk scores at population level. We cal-
culated the population distribution of different total
CVD risk categories both with and without adherence to
these practice notes. The notes state that those who have
blood cholesterol > = 8.0 mmol/l or persistent blood
pressure > = 160/100 mm/Hg should be considered in
the high-risk category regardless of risk calculations
using the charts. Further practice points in the WHO
guidelines point out that “CVD risk may be higher than
indicated by the charts” in those whose age or blood
pressure is approaching the next chart category and in
the presence of current antihypertensive therapy, prema-
ture menopause, obesity, sedentary lifestyle, socioeco-
nomic deprivation, close family history of CVD or
stroke, raised pulse rate, raised triglyceride or low HDL
cholesterol levels and a range of other biochemical
markers. Where possible, we identify individuals affected
by these additional risk factors and who therefore may
have a greater total risk than indicated by the charts.
The definitions used are as follows: raised triglycerides =
> 2.00 mmmol/l; low HDL cholesterol = < 1 mmol/l
(< 40 mg/dl) in males, <1.3 mmol/l (< 50 mg/dl) in fe-
males; on hypertensive medication = self-reported receipt
of medication for hypertension; obese = BMI > = 30 kg/
m2; sedentary lifestyle = physical inactivity assessed to be
<600 MET (metabolic equivalent) minutes per week asper International Physical Activity Questionnaire (IPAQ)
scoring protocol [22]; elevated pulse = resting pulse rate
>90 bpm [34-36].
For assessment of the prevalence in the populations of
individual risk factors, hypertension was defined as hav-
ing systolic blood pressure ≥ 140 mmHg or diastolic
blood pressure ≥ 90 mmHg, or measurements below
thresholds but self-reported anti-hypertensive medica-
tion. Hypercholesterolemia was defined as measurement
of total cholesterol ≥ 6.2 mmol/l (240 mg/dl) at the time
of survey, or measurement below threshold but self-
reported cholesterol-lowering medication.
Statistical methods
Analysis was conducted using STATA Version 11. Per-
centages and 95% confidence intervals were calculated
for categorical variables. Means and 95% confidence in-
tervals were calculated for scale variables. Using the
“svy:” function in Stata, weighted estimates were derived
from individual level data using WHO STEPS weighting
formulas that take into account sample weight (probabil-
ity of selection at all stages of survey cluster random
sampling: urban or rural district, subdivision or village,
household, within-household), non-response weight and
population weight to correct for age-sex variation be-
tween samples and target national populations.
Results
Distribution of individual risk factors used in total CVD
risk assessment
Table 2 presents the distribution of CVD risk factors for
people aged 40–64 years by age and sex. Cambodia, with
the lowest economic development status, has signifi-
cantly lower prevalence of all the risk factors except
smoking.
The prevalence of smoking and hypertension is higher
among men than women in all the three countries, al-
though the difference is not significant for hypertension
in Malaysia. No such consistent trend emerged for either
diabetes or high cholesterol. In Cambodia and Malaysia,
point estimates of both these risk factors were higher
among women, while the reverse was true in Mongolia.
The trends by age and sex should be noted as WHO/
ISH charts include both these demographic characteris-
tics as the key defining variables in the risk charts.
Population distribution of ‘total’ CVD risk using WHO/ISH
risk prediction charts alone
Table 3 shows the distribution of total CVD risk as per
WHO/ISH risk prediction charts. The majority of people
in all three countries has a low (<10%) 10-year CVD risk
ranging from 89.6% in Mongolia to 94.4% in Malaysia to
97% in Cambodia. The percentage of population at a
high CVD risk (≥20%) was the greatest at 6% in
Table 2 Prevalence of cardiovascular risk factors (HT, hypertension; DM, diabetes mellitus; HC, high cholesterol) in adults aged 40-64 years in Cambodia,
Malaysia, and Mongolia
Men Women Total




















































































































































































































































































































Table 3 Distribution of adult population aged 40–65 years into low (<10%), moderate (10% and < 20%) and high (≥ 20%) cardiovascular risk categories in
Malaysia, Mongolia and Cambodia*
Men Women Total
Age 40-49 50-59 60-64 40-64 40-49 50-59 60-64 40-64 40-49 50-59 60-64 40-64
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Cambodia. In all the three countries, a higher proportion
of men had moderate or high total CVD risk than
women, though in none of the countries were the differ-
ences statistically significant, and the risk among both
women and men increased significantly with age. The
age and gender differentials are to some extent endogen-
ous as both are used as risk factors inputs in calculation
of total CVD risk.
Estimation of population total CVD risk distribution after
inclusion of individuals with high levels of other risk
factors (per WHO guidelines for chart use in individuals)
Table 4 presents the proportions in each country of indi-
viduals classified as ‘high’ risk after adding those with
blood pressure ≥160/100 mm Hg to the chart-calculated
proportions as per WHO practice notes. This increases
the proportion of population with ‘high’ total CVD risk
from 1.3% to 4.8% in Cambodia, 2.3% to 7.7% in
Malaysia and 6.3% to 20.5% in Mongolia. The data on
population with cholesterol ≥8 mmol/l was available
only in Malaysia, and adding these individual to high-
risk category increased the population categorized as
high-risk in Malaysia to 9.6%. The proportions rise still
further to 10.4% in Cambodia, 20.8% in Malaysia and
33.3% in Mongolia if self-reported treatment for raised
blood pressure are also taken into account (Table 4).
Proportion of people in the low and moderate risk
categories with additional risk factors that may increase
the risk estimated by the charts
Several risk-increasing factors mentioned in practice
points accompanying WHO/ISH charts (obesity, seden-
tary lifestyle, raised pulse rate, raised triglycerides and
low HDL cholesterol) affect very large proportions of the
populations: 29% in Cambodia, 57% in Mongolia and
71% in Malaysia have at least one of the factors. If these
are added, outside the charts, it increases the proportion
of the population with CVD risk considerably. Of those
estimated to have low total CVD risk (<10%), approxi-
mately two thirds in Malaysia and Mongolia and one
third in Cambodia had at least one of these risk-
elevating factors. Of those at moderate risk, every case
in Mongolia (100%), nearly all in Malaysia (94.3%) and
one third in Cambodia (30.1%) had at least one risk-
elevating factor (Table 5).
Discussion
At 6%, 2.3% and 1.3% in Mongolia, Malaysia and
Cambodia respectively, the proportions of populations at
high CVD risk (≥20%) based on simple application of
WHO/ISH risk-prediction charts are in line with other
recent studies. Prevalence of high total CVD risk was es-
timated to be less than 10% in people aged 40 or over ineight LMIC countries: China 1.1%, Iran 1.7%, Sri Lanka
2.2%, Cuba 2.8%, Nigeria 5.0%, Georgia 9.6%, Pakistan
10.0% [10]. Another study in Seychelles reported 5.1% of
population (40–64 year old) with high total CVD risk in
2004 [11].
Use of CVD risk scores at a population level
Measurement and monitoring of trends in population-
level total CVD risk offers distinct advantages over
reporting on prevalence of individual risk factors (e.g.
hypertension, hyperlipidaemia, smoking, etc.) for assess-
ment of the total preventive treatment needs and the as-
sociated costs and to the net effectiveness of
interventions that affect multiple CVD risk factors by
different magnitudes and directions [23].
However, use of population CVD total risk as mea-
sured from cross-sectional surveys should be interpreted
taking into account some limitations. Our analysis sug-
gests that assessment of total CVD risk at population
level using current WHO/ISH charts may underestimate
the population with high total CVD risk and hence ac-
tual treatment needs. First, a recent systematic review
concluded that failure to take into account the effect of
treatment in the cohorts used to develop existing risk
scores charts may result in an inherent underestimation
of cardiovascular risk [37]. Second, applying risk score
charts to cross-sectional population data may underesti-
mate the risk if individuals already on treatment are not
taken into account; the degree of underestimation vary-
ing by the extent of drug treatment coverage and effect-
iveness. In this study, a substantial proportion of people
currently on treatment for hypertension and with their
blood pressure levels controlled were classified as low-
risk by simple application of WHO/ISH chart. The
underestimation of the high risk population is likely to
be greater in Malaysia than in Mongolia because of the
higher proportion of individuals on treatment. Third,
population surveys may not collect data that are re-
quired for thorough evaluation of total risk, such as fam-
ily CVD history or even history of current disease,
leading to further under-estimation. Hence, when indi-
viduals identified as high risk according to accompany-
ing practice points in WHO/ISH charts are included, the
proportions of populations at high risk in our study in-
crease markedly.
Other factors may lead to overestimation of CVD risk
at the population-level, as a measurement of blood pres-
sure on a single visit during survey may overestimate
population of people classified as hypertensive, and pro-
portion of population with blood pressure persistently
higher than 160/100 mmHg as required by WHO guid-
ance may be lower.
Despite these uncertainties, measurement and moni-
toring of population-level total CVD risk may provide
Table 4 Proportion of population% (95% CI) at different level of CVD risk with different inclusion criteria for the risk-factors
Inclusion criteria Cambodia (N = 3090) Malaysia (N = 1618) Mongolia (N = 845)
Low Mod High Low Mod High Low Mod High


































Chart + BP 60/100 BP + Cholesterol > =8 mmol/l na na na 89.0 (83.4-94.6) 1.4 (0.6-2.5) 9.6 (4.7-14.5) na na na





































Table 5 Prevalence of CVD risk enhancing factors not included in risk scores in WHO/ISH charts by risk category
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http://www.biomedcentral.com/1471-2458/13/539important guidance to help health planners to make in-
formed decisions for both treatment, needs assessment,
monitoring trends and impact of multi-factorial inter-
ventions [10,11]. Recently, WHO recommended moni-
toring proportion of people aged 40 years and over with
a 10 year CVD risk ≥30% on drug therapy and counsel-
ing as a way to measure health system response [38]. It
is likely that the true prevalence of WHO/ISH high
CVD risk lies somewhere between the lowest limit based
on simple application of WHO/ISH chart and upper
limit by taking into account high level of elevated single
risk factors and current treatment. Use of population
total CVD risk to assess efficacy of different interven-
tions should apply same criteria/risk scores to calculate
the CVD risk in each survey round as use of different
charts or criteria may substantially affect the outcome.
Recent research has suggested that the use of the total
CVD risk approach can help to reduce treatment costs as
opposed to ‘vertical approach’ estimating treatment needs
based on thresholds for individual risk factors This study
supports the earlier findings. Using predefined threshold
levels for hypertension as a single risk factor, as reported in
Table 1, 15.0%, 29.0% and 44.6% of the 40–64 year old pop-
ulations in Cambodia, Malaysia and Mongolia respectively
may require treatment for hypertension – assuming these
people could be identified in the population. This is much
greater than the 10.4%, 20.8% and 33.3% in Cambodia,
Malaysia and Mongolia, respectively estimated to be at high
CVD risk (≥30%) using WHO/ISH charts combined with
even the most inclusive practice points criteria (Table 4).
Risk scores used at an individual level
Utilized as intended at an individual level, the total risk ap-
proach offers important clinical benefits. Risk scores that es-
timate an individual’s total CVD risk can help clinicians to
ensure that individuals who are at greatest risk receive treat-
ment, a more cost-effective approach than treatment based
on a single elevated risk factor and with overall low total
CVD risk. However, emerging evidence from developed
countries suggests that despite availability of guidelines ad-
vocating the use of total risk scores instead of focusing on
single risk modification, adoption has been slow in these
countries [39,40]. It is unfortunate, however, that there is lit-
tle documentation of the implementation of the use of total
risk approach. Few studies have compared vertical and total
risk-assessment based treatment approaches. This should be
the topic for future implementation research, as clinicians
may be more likely to view favorably the adoption of a new
approach if there is evidence of better clinical outcomes as
well as cost-saving in drug treatment.
Need for ‘operational’ guidance
There may be need of considerable guidance and health
workers' training if the adoption of the total CVD riskapproach is to be effective in LMICs. Comprehensive
training or guidelines for clinicians in their use is re-
quired to ensure that adequate emphasis is given to the
practice guidance associated with the charts. The results
of this study highlight that a large proportion of popula-
tions in low- and moderate- risk categories have one or
more risk factors that increase their risk. This means
that, although the charts provide a valuable starting
point, health care workers have to use substantial clinical
discretion and a patient-centered approach when making
treatment decisions. The current total risk guidelines
also leave many questions unanswered so that further
guidelines may be required. For example, there is no
guidance on scenarios where health workers are unable
to determine diabetes mellitus status, but can only meas-
ure the blood pressure. And guidance on commencement
of antihypertensive drugs states that “all individuals below
160/100 mmHg, or with no target organ damage should
be managed according to CVD risk, and hence further
clarification is needed on whether target organ damage
adds significantly to the overall score in primary care facil-
ities in LMIC with little supporting infrastructure. Further,
operational guidance will also be needed on how to deal
with people who are already on treatment based on
single-factor approach or how to reassess CVD risk in this
group in order to fine tune the future treatment based on
current guidelines.Implication for change in screening strategies/criteria
Appropriate screening strategies will be required for
early identification of people with moderate to high
total CVD risk, but to date none of the countries ex-
amined here have formally introduced clinical guide-
lines either for screening or treatment based on total
CVD risk assessment, though Mongolia is in the
process of developing these guidelines.
Since most LMICs are yet to issue any guidelines
for screening and management of risk factors based
on total CVD risk assessment approach, it may be of
value to intensively pilot the implementation of WHO
guidelines using WHO/ISH risk prediction charts in
primary care settings to fully understand the oper-
ational issues including the ease of their application
by different categories of health workers, the level of
additional training required and issues and scenarios
requiring clear guidance. In addition, validation of the
charts should be completed before advocating large-
scale use, considering the substantial resource invest-
ments required in training large health workforce in
use of the guidelines.
Use of population-level total CVD risk in monitoring
the impact of different interventions over-time should
also be validated with analysis of trends data.
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Measurement of total CVD risk offers a distinct advan-
tage to monitor impact of multi-factorial interventions
overtime and to assess total preventive treatment needs.
Risk scores that estimate an individual’s total CVD risk
can help ensure that individuals with higher total CVD
risk, especially men and older people, do not go without
essential preventive treatment because of the absence of
single significantly elevated risk factors. However, coun-
tries need to develop overall clinical guidelines for op-
portunistic screening and management together with
operational guidance for health workers at different
levels of health system in order to apply a cost-effective
approach for the detection and management of patients
at high CVD risk, rather than basing treatment decisions
on a single risk factor. Further operational research is
needed to examine issues that may be faced in their
implementation.
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